Safety and tolerability of xanomeline and trospium chloride in schizophrenia: Pooled results from the 5-week, randomized, double-blind, placebo-controlled …
1. 系统已在2025-08-24 17:03:39对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.4088/JCP.24m15497
文献链接: https://pubmed.ncbi.nlm.nih.gov/40047530/
其他信息:
I Kaul, A Claxton, S Sawchak, C Sauder…
J Clin …, 2025
psychiatrist.com
Objective: To further characterize the safety and tolerability of oral xanomeline and trospium chloride in the treatment of people with schizophrenia experiencing acute psychosis. Methods: Pooled analyses were performed on safety data from the 5-week, randomized, double-blind, placebo-controlled, inpatient EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials of xanomeline/trospium in adults with schizophrenia with a recent worsening of psychosis requiring hospitalization. Adverse events (AEs) including extrapyramidal motor …
